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Background-—Mutations in the POT1 gene explain abnormally long telomeres and multiple tumors including cardiac
angiosarcomas (CAS). However, the link between long telomeres and tumorigenesis is poorly understood.
Methods and Results-—Here, we have studied the somatic landscape of 3 different angiosarcoma patients with mutations in the
POT1 gene to further investigate this tumorigenesis process. In addition, the genetic landscape of 7 CAS patients without
mutations in the POT1 gene has been studied. Patients with CAS and nonfunctional POT1 did not repress ATR (ataxia telangiectasia
RAD3-related)–dependent DNA damage signaling and showed a constitutive increase of cell cycle arrest and somatic activating
mutations in the VEGF (vascular endothelial growth factor)/angiogenesis pathway (KDR gene). The same observation was made in
POT1 mutation carriers with tumors different from CAS and also in CAS patients without mutations in the POT1 gene but with
mutations in other genes involved in DNA damage signaling.
Conclusions-—Inhibition of POT1 function and damage-response malfunction activated DNA damage signaling and increased cell
cycle arrest as well as interfered with apoptosis, which would permit acquisition of somatic mutations in the VEGF/angiogenesis
pathway that drives tumor formation. Therapies based on the inhibition of damage signaling in asymptomatic carriers may diminish
defects on cell cycle arrest and thus prevent the apoptosis deregulation that leads to the acquisition of driver mutations. ( J Am
Heart Assoc. 2019;8:e012875. DOI: 10.1161/JAHA.119.012875.)
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T he Li-Fraumeni syndrome is an autosomal dominantsyndrome representing a genetic predisposition to a
wide spectrum of tumors and is typically linked to mutations
of the TP53 tumor suppressor gene.1 Li-Fraumeni-like families
have a similar clinical presentation, but Li-Fraumeni-like
syndrome is less frequently associated with mutations in the
TP53 gene. Recently, we studied different Li-Fraumeni-like
families with multiple tumors including various cases of
cardiac angiosarcoma (CAS), which is the most common and
most aggressive type of primary malignant neoplasm of the
heart in adults.2 Patients affected with CAS are generally
diagnosed at advanced stages with very poor prognosis and
From the Human Genetics Group (O.C., J.B.), Tumour Suppression Group (L.M.), Biobank Unit (M.M.M.), and Familial Cancer Clinical Unit (M.U.), Spanish National
Cancer Research Center (CNIO), Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain (O.C., J.B.); Department of
Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain (P.G.-P., F.D., M.G.C.-L.); Center for Biomedical Network Research on Cardiovascular Diseases
(CIBERCV), Madrid, Spain (P.G.-P., F.D.); Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria (UFV), Madrid, Spain (P.G.-P.); Spanish National
Cardiovascular Research Center (CNIC), Madrid, Spain (F.D.); Medical Genetics Unit, Sistemas Genomicos, Parque Tecnologico de Valencia, Paterna, Spain (L.P.-C.,
D.C.); Department of Cardiology, Hospital Universitario y Politecnico La Fe, Valencia, Spain (E.Z.); Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain
(T.R.yC.); Department of Cardiology, Instituto de Investigacion Biomedica de A Coru~na (INIBIC), Complexo Hospitalario Universitario de A Coru~na (CHUfSiAC), A Coru~na,
Spain (M.G.C.-L.); Hereditary Cancer Program-Medical Oncology Service (A.T.) and Medical Oncology Service (C.L.), Catalan Institute of Oncology, ICO-IDIBELL and
CIBERONC, Barcelona, Spain.
Accompanying Tables S1 through S5 are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.012875
Correspondence to: Oriol Calvete, PhD, Spanish National Cancer Research Center (CNIO), Melchor Fernandez Almagro, 3. 28029, Madrid, Spain. E-mail:
ocalvete@cnio.es or Javier Benitez, PhD, Spanish National Cancer Research Center (CNIO), Melchor Fernandez Almagro, 3. 28029, Madrid, Spain. E-mail:
jbenitez@cnio.es
Received April 8, 2019; accepted July 22, 2019.
ª 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.





 http://ahajournals.org by on Septem
ber 24, 2019
short survival rates (5-year survival rate of 14%).3 The genetic
landscape that determines the tumorigenic process of
angiosarcomas (AS) is poorly understood and not well
established.4,5 Previous studies by our group uncovered a
deleterious missense mutation in the POT1 gene (c.349C>T
[p.Arg117Cys], pathogenic, Li-Fraumeni-like syndrome/CAS,
autosomal dominant)6 causing AS in 4 families (3 in cardiac
tissue and 1 in breast).6 Germline mutations in the POT1
gene have also been related with the development of other
familial cancer types.7-12 POT1 is a component of the so-
called shelterin complex, which is involved in telomere
elongation in germline and stem cells (Figure 1A).13 In normal
conditions the shelterin complex protects telomere cap ends
in somatic cells by preventing access of the telomerase to
chromosome ends.14 The shelterin complex also masks
single-stranded telomeres from the DNA damage response,
thereby preventing the activation of ATM (ataxia telangiec-
tasia mutated) and ATR (ataxia telangiectasia RAD3-related)
to avoid cell cycle arrest through POT1 and TPP1 (Fig-
ure 1B).15 TPP1 (which is also called ACD gene) anchors the
telomere by POT1 and TRF1 (telomeric repeat binding factor
1) proteins. When telomeres are critically short, the shelterin
complex does not prevent activation of the ATM and ATR
response, which can drive the cell to senescence and
apoptosis (Figure 1C).
Our previous studies demonstrated that cardiac angiosar-
coma patients carrying the POT1 p.Arg117Cys mutation
showed abnormally long telomeres due to the lack of
repression of telomerase, which led to increased fragility
and damage.6 Other described POT1 mutations associated
with risk of developing familial glioma and familial
melanoma tumors also led to abnormally long and fragile
telomeres.7 However, the link between telomere instability
and tumorigenesis is not well understood. In addition,
studies of the biological pathways involved in the progres-
sion of angiosarcomas are very scarce. Recently, next-
generation sequencing studies uncovered somatic alter-
ations in the VEGF/PLCG1 pathway in cardiac angiosar-
coma16,17 and driver mutations in the PI3K/AKT/mTOR and
MEK pathways in angiosarcomas other than cardiac,18-21 but
these studies did not distinguish between constitutive and
somatic mutations and did not clarify the genetics and
underlying mechanisms.
In order to understand how telomere instability links the
angiosarcoma process, in the present work we studied
somatic events in different angiosarcoma patients carrying
the POT1 p.Arg117Cys mutation described in Calvete et al6: 2
patients (F1 and F3) affected with CAS and 1 patient (F2) with
2 tumors, a breast AS and a papillary thyroid tumor. In
addition, we studied the genetic and molecular somatic
landscape that drives tumor progression in 7 patients with
sporadic CAS tumors (NT1-NT3 and T1 to T4) who did not
carry mutations in the POT1 gene.
Methods
The data, methods used in the analysis, and materials used to
conduct the research are available to any researcher for
purposes of reproducing the results or replicating the
procedure.
Ethics Statement
Institutional Review Board approval was obtained; the ethics
committee of the CNIO, the Institute of Health Carlos III, and
SaludMadrid (Autonomous Community of Madrid) approved
this study (CS9679). Informed consent was received from
participants before inclusion in the study.
Patients
Formalin-fixed paraffin-embedded (FFPE) tissue samples from
10 patients were selected. The 3 familial angiosarcoma
individuals carrying the POT1 p.Arg117Cys mutation were
selected from Calvete et al.6 Seven FFPE tissue samples from
individuals affected with sporadic CAS not carrying mutations
in the POT1 gene were also selected: 3 FFPE tissue sections
contained normal (N) and tumor (T) tissue (NT1, NT2 and
NT3), and the other 4 FFPE sections contained only tumor
tissue (T1 to T4).
Clinical Perspective
What Is New?
• In this study we describe how mutations in the POT1 gene,
which explain long telomeres, correlate with cell cycle arrest
increase in angiosarcoma patients.
• The same increase was observed in other cardiac angiosar-
coma patients even without mutations in the POT1 gene but
in the damage response signaling.
• This malfunction would bypass the apoptosis mechanism
and would trigger the acquisition of somatic activating
mutations in the angiogenesis pathway.
What Are the Clinical Implications?
• Our results suggest that the use of angiogenesis inhibitors
might regulate the tumor progression; however, targeting
ATM/ATR (ataxia telangiectasia mutated/RAD3-related)
activity would rescue the cell cycle control and would
prevent the acquisition of somatic driver mutations in
patients affected with angiosarcoma tumors and asymp-
tomatic patients carrying POT1 mutations.
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Samples
Genomic DNA was extracted from FFPE tissue samples and
from fixed tissue slides (microdissection) using the DNeasy
Blood & Tissue Kit (Cat No. 69504, Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Histology of hema-
toxylin and eosin–stained sections of the tissues was
assessed by a pathologist (M.M.).
Immunohistochemistry
FFPE blocks were cut into 5-lm-thick sections for immuno-
histochemistry (IHC) studies. The cell cycle in normal tissue
was tested with anti-p21 (WAF1) from Merck (Darmstadt,
Germany; Ref MABE325), anti-p27 (57/Kip1) from BD Bio-
sciences (Franklin Lakes, NJ; Ref 610242), and anti–phospho-
histone cH2AX (Ser139) from Millipore (Burlington, MA; Ref
05-636) antibodies. Activation of the VEGF-angiogenesis
pathway was assessed with 2 different antibodies against
phosphorylated (activated) proteins: anti–phospho-p44/42-
MAPK (ERK1/2) and anti–phospho-S6 ribosomal protein
(Ser235/236) from Cell Signaling Technology (Danvers, MA;
Refs 9101 and 2211, respectively). Both the absence of
staining and excess nonspecific staining were considered as
negative staining. Staining was considered separately in
normal (N) and tumor (T) tissues. IHC controls were performed
by using normal tissue from biopsies of healthy individuals.
Whole Exome Sequencing and Bioinformatics
Pipelines
Exomes from selected tissues were captured and enriched
using the SureSelect Human All Exon Kit (78 Mb) (Agilent
Technologies, Santa Clara, CA). Enriched samples were
paired-end sequenced on an Illumina Genome Analyzer II
sequencing platform using 2 lanes per sample and generating
101 base-pair long reads. FASTQ files of short reads were
aligned using the BWA algorithm to the GRCh37/hg19
reference genome22; 96.11% (ranging from 93.34% to
98.74%) of the reads aligned in the reference genomes
(effectiveness). GATK-based variant calling was performed for
aligned reads considering DP (Read Depth) values of >30 and
Quality-by-Depth scores for a variant confidence of >1.00. A
total of 92.28% (ranging from 91.70% to 92.16%) of the
variants that were well aligned and annotated passed the
quality and coverage filters. Strict filtering for only well-
defined variants by quality controls, and those not included in


















C  Extremely short telomere
ATM
ATR





















Figure 1. Telomere biology and damage signaling. A, Elongation in germline/stem cells. The shelterin complex mediates telomere elongation by
recruiting telomerase. Shelterin also represses the DNA damage response by preventing the activation of ATM and ATR through TPP1 and POT1
proteins, respectively. TPP1 is anchored to the chromosome by POT1 and TRF (telomeric repeat binding factor 1), which is another component of
the shelterin complex. B, Telomere shortening in somatic cells. Somatic divisions entail telomere shortening due to the inhibition of telomerase
recruitment mediated by the POT1 protein. C, Extremely short telomere. The shelterin complex cannot bind critically short telomeres. DNA
damage response ATM/ATR activates the TP53/p21 cascade to inhibit CDK1/2. DNA damage markers such as cH2AX and TP53BP1 bind the
short telomeres. DNA damage signaling mediates senescence, cell cycle arrest, and apoptosis. D, POT1 p.Arg117Cys (p.R117C) mutation
carriers. The POT1 p.R117C mutation prevents POT1 from binding to TPP1 and from forming the OB-fold to bind single-strand DNA, which
prevents POT1 from repressing ATR signaling. Telomere damage response is activated in POT1 p.R117C mutation carriers.
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variants (<10% alternative variant allele frequency) and those
with low coverage (<69) were discarded.
Only quality-filtered variants affecting coding sequences of
canonical transcripts (nonsynonymous, essential splice site,
frame shift or gain/loss of stops) were taken into account.
Variant type annotation, population statistics, disease-specific
sequence databases, and in silico predictive algorithms were
according to AMCG standards and guidelines.23 Variants with
a minor allele frequency of <0.01 and <0.05 (dbSNP130,
HapMap, or 1000 Genomes) were considered for stringent
and relaxed filtering, respectively. Their potential damaging
effect was assessed using the VEP24 script software package
(including Sift, Polyphen and Condel damage predictors).
Stringent filtering only considered the variants annotated as
pathogenic by all damage predictors. Whole-exome sequenc-
ing data have been deposited in the ArrayExpress public
database under accession number E-MTAB-7999 (available at
https://www.ebi.ac.uk/fg/annotare/).
Variants found in DNA blood samples and variants found in
common between paired normal/tumor tissues were consid-
ered as constitutional. Variants found only in tumor tissue
were considered somatic variants. Constitutional variants
were validated in DNA from blood and normal tissue samples,
and somatic variants were validated in DNA from tissue
samples (tumor) by Sanger sequencing.
Pathway Enrichment Analyses
Two different software packages were used for independent
assessments of the gene set analyses. Data were analyzed
with Qiagen’s Ingenuity Pathway Analysis (IPA, Qiagen,
Redwood City, CA www.qiagen.com/ingenuity) and Consen-
susPathDB (available at http://cpdb.molgen.mpg.de/).25
Overrepresentation analysis of the gene set list was per-
formed with a minimum overlap of 4 genes with the pathway
database set size and a P-value cutoff of 0.001. Induced
network module analysis without intermediate nodes and
considering high-confidence binary protein and genetic/gene
regulatory interactions were also evaluated.
Trusight Tumor 170 Panel and IBM Watson Study
Resequencing of tumor DNA from FFPE tissue samples was
performed with TruSight Tumor 170 from Illumina (San Diego,
CA), a novel sequencing platform that predicts the most
probable variant causing the pathology and provides sugges-
tions for translating the data to the clinic. The sequencing of the
hybrid capturewas run on theHiSeq 2500 System. The captured
gene content in the TruSight Tumor 170 Assay, data sheet, and
specifications are available at https://www.illumina.com. Low
variant quality of <20 and low depth (<100 for variant calls and
<250 for reference call filters) were considered. Variants were
supported with >7 reads and filtered by frequency (minor allele
frequency<0.05). The copy number variation call was calculated
for the fold-change results for each gene. Variants were
classified and analyzed later by the IBM Watson for Genomics
platform, which searches electronic medical databases to find
information that may be relevant to a particular genomic
sequence (available at https://www.ibm.com/watson/).
Results
Angiosarcoma Patients Carrying the POT1
p.Arg117Cys Mutation
Constitutional Effect in Normal Tissue of POT1
p.Arg117Cys Mutation Carriers
In normal conditions the POT1 protein represses downstream
activation of the DNA damage response at telomeres in
somatic cells (Figure 1B).15 The POT1 p.Arg117Cys protein
shows a reduced capacity to bind telomeres and TPP16 and
may affect the regulation of the damage response. Damage
response activation leads to cell cycle arrest, replicative
senescence, and apoptosis (Figure 1C). In order to decipher
the putative effect of POT1 malfunction, patient tissues were
stained with anti-P-cH2AX (DNA damage marker) and anti-p21
and anti-p27 antibodies (inhibitors of CDK1/2 to arrest the
cell cycle). IHC studies were carried out in normal (N) tissues
of patients from the families carrying the constitutional POT1
p.Arg117Cys mutation studied in Calvete et al6: 2 patients
(F1 and F3) affected with CAS and 1 patient (F2) with 1 breast
AS and 1 papillary thyroid tumor.
Increased IHC staining with anti-p21, -p27, and -P-cH2AX
antibodies was observed in N tissues of all studied patients in
comparison with the corresponding N tissues from healthy
non–mutation carriers (Table 1 and Figure 2A). Therefore, the
reduced binding to telomeres and to TPP1 by the POT1
p.Arg117Cys protein correlates with activation of damage
response signaling mediated by p21 and p27 (Figure 1D).
Somatic Events in POT1 p.Arg117Cys Mutation
Carriers
To evaluate possible somatic events in affected individuals
carrying the POT1 p.Arg117Cys mutation that might lead to
the formation of AS, the exomes of normal (N) and tumor (T)
tissues of the F1 and F2 individuals were sequenced. Variants
found in T tissue but not in N tissue were considered to be
somatic (Table S1). In patient F1 (CAS), 46 filtered somatic
variants were found in T but not in N cardiac tissue (Table 2)
including an in-frame deletion in the KDR gene (p.Asn704del),
which encodes VEGF receptor 2 (VEGFR2), which belongs to
the VEGF-angiogenesis signaling pathway (Figure 3A and 3B).
Regarding the F2 individual, only 13 filtered somatic
variants were found in the T tissue of the breast AS
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(Table S1). Two of them were variants annotated in the genes
PLCG1 (p.Leu752Val) and PIK3CA (p.Arg88Gln) belonging to
the VEGF-angiogenesis pathway and previously described to
be involved in different angiosarcomas and primary breast
cancer.26 Another 5 somatic variants were found in the
papillary thyroid T tissue from the same individual (Table S1).
Three of these belonged to the VEGF-angiogenesis pathway
(PIK3R6 [p.Arg59Lys], RASSF1 [p.Arg227His], and BRAF
[p.Val600Glu]). Overall, 32/52 (62%) of the somatic missenses
were C:G>T:A changes (Table S1). Genes with mutations are
shown in the angiogenesis pathway depicted in Figure 3.
Finally, only cardiac tumor tissue from patient F3 (CAS)
was sequenced (Table 2). A total of 297 filtered variants were
found in the tumor tissue of this patient (Table S2), including
another mutation in the KDR gene (p.Thr771Arg). Overall, 60%
of the somatic variants found in patient F3 were annotated as
C:G>T:A changes (Table S2).
Thus, somatic mutations in the VEGF signaling pathway
were found in the tumor tissues of all affected individuals
carrying the POT1 p.Arg117Cys germline mutation. Interest-
ingly, both studied CAS patients had mutations in KDR, which
activates VEGF signaling to regulate angiogenesis by the
MAPK/ERK and AKT/PI3K pathways (Figure 3A and 3B).
MAPK/ERK regulates proliferation activity, while AKT/PI3K
promotes protein synthesis. Interestingly, both molecular
activities regulate the cell cycle by inhibiting senescence
promotion (Figure 3C). In order to test the putative effects of
the mutations found in the VEGF angiogenesis pathway, we
studied the MAPK/ERK and AKT/PI3K molecular pathways by
IHC with antibodies against the activated (phosphorylated)
forms of ERK and S6, respectively (Figure 3A and 3B). All
angiosarcomas (CAS and the breast AS tumors) did not stain
with anti–P-ERK but were positively stained (>70%) with the
anti–P-S6 antibody. However, papillary thyroid tumor tissue
stained with both antibodies (Table 1 and Figure 2B).
In summary, somatic activating mutations of the VEGF-
angiogenesis pathway were found in all studied tumor tissues
of POT1-mutated patients independently of the tumor type
(cardiac, breast, and thyroid). Somatic mutations in the KDR
gene were found in both CAS patients (F1 and F3). In addition,
positive P-S6 staining was observed in all angiosarcomas with
somatic mutations in the KDR (CAS) and PI3K (breast AS)
genes (AKT/PI3K pathway). The papillary tumor (F2), which
had a mutation in the MAPK/ERK signaling pathway (BRAF
gene), was stained with both anti–P-ERK and anti-PS6
antibodies (Figures 2B and 3).
Sporadic Cardiac Angiosarcoma Patients Without
Mutations in the POT1 Gene
To assess the whole genetic landscape of CAS tumors,
another 7 patients with sporadic CAS tumors who were not
Table 1. Total Cases and Number of Variants Found in the Whole Exome Sequencing
Individual Pathology Tissue Variant Calling Filtered Variants Somatic Variants* Constitutional Variants†
POT1 p.Arg117Cys carriers F1 CAS T 1095 46 NA+
N
F2 Papillary thyroid T 100 506 1294 5 NA+
N 100 371 1281
Breast AS T 93 496 1276 13 NA+
Without mutations in
the POT1 gene
NT1 Sporadic CAS T 102 560 1266 62 1032
N 111 686 1333
NT2 Sporadic CAS T 100 120 1231 36 1101
N 141 248 1239
NT3 Sporadic CAS T 97 233 704 37 1180
N 113 358 762
Individual Pathology Tissue Variant Calling Filtered Variants Stringent Filtering
Only T tissue available‡ T1 Sporadic CAS T 93 374 1181 315
T2 Sporadic CAS T 95 492 1274 403
T3 Sporadic CAS T 104 545 1328 443
T4 Sporadic CAS T 93 859 1233 361
CAS indicates cardiac angiosarcoma; N, normal tissue; NA+, not applicable (POT1 p.Arg117Cys carriers from Calvete et al [2015]); T, tumor tissue.
*Variants found in tumor tissue that were not found in normal tissue.
†Variants found in normal tissue that were not found in tumor tissue.
‡Individuals with only T tissue sequenced.
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Figure 2. Immunohistochemical staining. A, Tissue stress was tested in normal tissue of carriers of the POT1
p.Arg117Cys (p.R117C) mutation and carriers of mutations in the damage response-signaling pathway (sporadic
CAS) in comparison with the corresponding normal tissue without mutations (wild type). Above: Wild-type cardiac
and thyroid tissues from healthy controls without mutations. Below: normal tissue of individual NT2 (sporadic
CAS individual with constitutional mutations in the ATR, ATM and TP53BP genes) and normal tissue of individual
F2 (papillary thyroid tumor with POT1 p.R117C mutation) as representative examples (see Table 2 for all studied
individuals). Increased cell cycle arrest was observed in the normal tissue of both patients. Black arrowheads
show some of the stained nuclei. Detailed fields (109) are also shown. Scale bar (in black): 100 lm. B, IHC
staining with anti–P-ERK and anti–P-S6 antibodies in tumor tissues. Tumor tissues from carriers (F1 and F2) and
noncarriers (T1 and NT2) of the POT1 p.R117C mutation compared with a normal tissue section (negative
staining) are shown as examples (see Table 2 for all studied individuals). Three tumors from the 2 patients (F1 and
F2) carrying the POT1 p.R117C mutation are shown: both angiosarcomas (CAS tumor tissue from F1 and breast
AS from patient F2) only showed immunoreactivity with anti–P-S6 antibody, while the papillary thyroid tumor
(patient F2) also showed immunoreactivity with anti–P-ERK antibody. Two staining patterns were observed in
sporadic CAS patients without mutations in the POT1 gene: tissue from patient T1 only showed immunoreactivity
with anti–P-S6, whereas tissue from patient NT2 (sporadic CAS) was stained with both anti–P-S6 and anti–P-ERK
antibodies. Scale bar (in black): 100 lm. AS indicates angiosarcoma; CAS, cardiac angiosarcoma; N, normal
tissue; T, tumor tissue.
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carrying mutations in the POT1 gene were studied. Normal (N)
and tumor (T) cardiac tissues were available from 3 sporadic
CAS individuals (NT1, NT2, and NT3), whereas only tumor
tissue was available from the other 4 CAS individuals (T1 to
T4). We found 1032, 1101, and 1180 constitutional variants
in cardiac tissue for the NT1, NT2, and NT3 CAS individuals,
respectively; 62, 36, and 37 somatic variants were found for
individuals NT1, NT2, and NT3, respectively (Table 2).
Regarding the 4 tumor samples of which only T tissue was
available, no distinction could be made between constitutional
and somatic variants. We found 1181, 1274, 1328, and 1233
variants in the T tissue of patients T1, T2, T3, and T4,
respectively (Table 2).
To further delineate the genetic landscape of sporadic CAS
tumors, the genes encompassing filtered variants were
grouped into 2 different pathway enrichment analyses. The
first set included genes with constitutional (found in both N
and T tissues from cases NT1, NT2, and NT3) and all genes
with variants from the other 4 CAS individuals with only the
tumor tissue sequenced (constitutional or somatic) (2501
unique genes in total); the second set included the genes with
somatic variants (only present in T tissue) from cases with N
and T tissue (NT1, NT2, and NT3) and again all genes with
variants from the other 4 CAS individuals with only the
sequenced T tissue cases (T1 to T4) (1522 unique genes in
total).
Constitutional Events in Normal Tissue in Sporadic CAS
This study revealed that the most represented pathway and
the pathway with the major number of genes were the
“Sustainability of p53 pathway” (genes ATM, TP53, and
RFWD2) (P value 0.003) and the “Repair modulation pathway”
(genes ATR, ATM, TP53, RFWD2, SIRT7, BRCA2, CDK8,
UBE2D1, WRN, PMS2, BRIP1, TP53BP2, and APC2) (P value
0.0022), respectively (Table S3). Mutations in genes from
these pathways were found in all 7 sporadic CAS individuals
(Figure 4). These genes belong to the damage response
signaling pathway and may deregulate the cell cycle in the
same manner as previously observed for the POT1 mutation
carriers. Thus, N cardiac tissue from the sporadic CAS
individuals (NT series) was also stained with anti–P-cH2AX,
anti-p21, and anti-p27 antibodies. Positive staining was also
observed in N tissue of sporadic CAS individuals (Table 1),
which correlated with cell cycle deregulation as observed in
familial angiosarcomas (POT1 p.Arg117Cys mutation carriers).
Therefore, the familial angiosarcomas (POT1 p.Arg117Cys
carriers) and sporadic CAS patients behaved in a similar way
regarding cell cycle arrest regulation.
Somatic Events in Tumor Tissue in Sporadic CAS
A second pathway enrichment analysis was performed with
the gene set including the somatic variants found in T tissues
of sporadic CAS individuals (see above). This enrichment
analysis revealed that the most represented pathway was the
“gf-hypoxia and angiogenesis” pathway (Biocarta: 16.7%)
(P value 0.00557). The pathway with the major number of
affected genes was the “Signaling by VEGF” pathway
(Reactome, 24 genes) (P value 0.00101) (Table S3). Both
enrichment analyses corresponded with the VEGF-angiogen-
esis pathway. Genes with mutations are shown in the
angiogenesis pathway of Figure 3. Mutations in genes from
these pathways were found in all 7 sporadic CAS individuals
(Figure 4). Activation of the MAPK/ERK and AKT-PI3K path-
ways was studied by IHC with anti–P-ERK and anti–P-S6
antibodies, respectively.
Tumors of all studied sporadic CAS individuals (NT and T
series) stained positive with anti-PS6 antibodies, which
demonstrates that somatic mutations were activating the
VEGF-angiogenesis pathway (Table 1). Especially intense
staining was also observed in the endothelial lining of blood
vessels. However, not all tissues from individuals affected
with sporadic CAS stained with anti-PERK antibody. Tissue of
Table 2. Immunohistochemistry Staining Results for the Studied Cases
Mutation Sample Pathology Tissue
N Tissue
Mutations in VEGF-Angiogenesis Pathway
T Tissue
cH2AX p21 p27 P-ERK P-S6*
POT1 F1 CAS Cardiac (N+T) + + + KDR  +
p.Arg117Cys F2 Breast AS Breast T NA NA NA PI3K  +
Thyroid (N +T) + + + BRAF + +
DR genes NT2 CAS Cardiac (N+T) + + + VEGF2/RAS-MAPK + +
T1 CAS Cardiac (T) NA NA NA Akt-PI3K  +
T3 CAS Cardiac (T) NA NA NA RAS-MAPK/Akt-PI3K + +
T4 CAS Cardiac (T) NA NA NA VEGFA/Akt-PI3K + +
+ indicates overexpression; , no expression; CAS, cardiac angiosarcoma; DR, damage response; N, normal; NA, tissue not available; T, tumor.
*Positive staining in lining epithelium and tissue.
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individual T1, who only had mutations in the AKT-PI3K
signaling pathway (Table 1), did not stain with anti–P-ERK.
The tumors with mutations in the 2 molecular signaling
pathways (NT1, NT2, and T4) also stained positive with the 2
antibodies (anti–P-ERK and anti–P-S6) (Table 1). Interestingly,
the individual with mutations only in the MAPK/ERK signaling
pathway (T3) also stained positive with both antibodies
(Table 1). Stained tissues from patients T1 and NT2 are
shown in Figure 2B as representative examples.
In summary, all studied individuals with CAS (either familial
or sporadic) had mutations (either constitutional or somatic)
in normal tissue affecting damage response signaling (Fig-
ure 4). IHC with anti-p21 and anti-p27 antibodies confirmed
cell cycle arrest deregulation in N tissue that leads to
constitutional cell cycle arrest and cessation of cell division
(Figure 2A and Table 1). In addition, somatic activating
mutations in the VEGF-angiogenesis pathway were found in
tumor tissue of familial and sporadic angiosarcomas, inde-
pendently of the presence of POT1 mutations (Figures 2B and
4; Table 1).
Sequencing Replication With the Truseq170
Panel and IBM Watson for Genomics Platform
A sequencing replication was performed for 2 previously
sequenced CAS patients without mutations in the POT1 gene.
The Truseq170 panel was run for tumor tissue of the T1 and
T4 individuals and analyzed with the IBM Watson for
Genomics platform (version 33.148), which is a novel
sequencing platform that predicts the most probable variant
causing the pathology and provides suggestions for translat-
ing the data to the clinic. The Watson for Genomics pipeline
revealed 15 variants of unknown significance, 2 alterations
without proposed therapies, and only 1 actionable alteration
for patient T1 (Table S4). Three variants of unknown
significance, 3 alterations with no proposed therapies, and
another 3 actionable alterations were described for patient T4
(Table S5). Interestingly, a not previously detected copy
number gain was found for the KIT gene in the tumor tissue of
patient T1. The gained region is involved in tumor cell
proliferation, angiogenesis, and metastatic disease. Only 1
actionable pathway was found in common for both CAS
patients. The variants found in the TP53 gene were highlighted
as actionable alterations, as previously found in the WES
study (TP53 p.Arg175His and TP53 p.Val143Met for patients
T1 and T4, respectively). No Food and Drug Administration–
approved therapies for angiosarcoma were recommended for
these 2 patients, but 3 therapies with clinical trials were
observed in common for both patients: AZD1775 (NCT
numbers NCT02576444 and NCT018227384), Transferrin
Receptor-Targeted Liposomal p53 (NCT02354547), and Mod-
ified Vaccinia Virus Ankara Vaccine (NCT02432963). The 3
therapies for the alterations common to the 2 CAS patients
target TP53 to restore cell cycle regulation.
Discussion
Telomere Instability in POT1 Mutation Carriers
Increases Cell Cycle Arrest in Constitutional
Tissue and Increases Acquisition of Somatic
Mutations in the Angiogenesis Pathway
The single-strand DNA response in telomeres is inactivated
by the shelterin complex (Figure 1A and 1B).15 We previously
observed that the POT1 p.Arg117Cys mutation prevented the
POT1 protein from binding to TPP1 and forming the OB-fold
to bind singles-strand DNA, which led to abnormally long
telomeres.6 Here, we observed that abnormal telomere
length found in our patients correlates with a genomic
instability scenario that, in consequence, activates DNA
damage-signaling (cH2AX-positive staining). Individuals car-
rying the POT1 p.Arg117Cys mutation overexpressed the
p21 and p27 proteins in constitutional tissue (Table 1),
which correlates with prevention of the repression of ATR
signaling and leads to cell cycle arrest (Figure 1D). This
increased senescence in nontumor tissue would result in
reduced cell cycling and cessation of cell division. A similar
mechanism was proposed to explain how short telomeres
can lead to vascular senescence and diminished proliferative
capacity that involved exhaustion of cell pools in mice.27,28
In addition, tumor tissue of POT1 p.Arg117Cys mutation
carriers was studied in order to evaluate the involvement of
constitutional cell cycle arrest in tumor progression. On
average, 61% of the somatic variants found in these patients
were C:G>T:A changes (Tables S1 and S2). At this time we
cannot rule out a correlation between this observed bias and
a specific mutation signature in these tumors. Megquier
et al29 have established an association with somatic deam-
ination of cytosine to thymine in a large series of angiosar-
comas (different from cardiac), which is in agreement with
our observation. Somatic mutations in the VEGF-angiogen-
esis pathway were found in tumor tissue of all individuals
(Figure 4). Interestingly, the F1 and F3 individuals (CAS) also
had a somatic mutation in the KDR gene, which is involved in
VEGF/PLCG1 activation and was described altered in 2
recently studied sporadic CAS cases.16,17 In the F2 patient
the recurrent somatic mutations PIK3CA p.Arg88Gln and
BRAF p.Val600Glu were found in the breast AS and the
papillary thyroid tumor, respectively. Twenty-five percent of
all breast cancers have somatic mutations in the PIK3CA
gene. Specifically, the PIK3CA p.Arg88Gln mutation was
described in a primary breast cancer.26 The somatic
mutation BRAF p.Val600Glu is the most common genetic
change in papillary thyroid cancers (35.8%).30 In addition, the
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BRAF p.Val600Glu and PIK3CA p.Arg88Gln mutations have
been described as activators of the angiogenic response.31,32
The somatic mutation BRAF p.Val600Glu has also been
reported in gliomas33 and melanomas,34 where constitutional
mutations in the POT1 gene were also described.10-12 In
summary, individuals with nonfunctional POT1 did not
repress damage signaling (ATR) and showed a constitutive
increase of p21 and p27 expression, which is in agreement
with cell cycle arrest. In addition, somatic activating
mutations in the angiogenesis pathway were acquired.
Interestingly, activating somatic mutations in the KDR gene
were found in both studied patients affected with CAS and
carrying a POT1 germline mutation (F1 and F3). This was
also observed in other tissues and tumors different from
cardiac angiosarcomas with mutations in the POT1 gene
(thyroid and breast from patient F2), demonstrating that not
only in cardiac tissue is there a strong correlation between
constitutional senescence mediated by POT1 malfunction
and the acquisition of somatic mutations in the angiogen-
esis pathway.
Sporadic Cardiac Angiosarcomas Without POT1
Mutations
Although in 4 of the 10 patients studied no discrimination
between germline and somatic mutations could be made,
mutations in the pathways that were affected by the mutation
in the POT1 gene at both the constitutional and the somatic
level were also found in these patients.
Studied CAS individuals without constitutional mutations in
the POT1 gene presented mutations in genes that were
involved in damage response signaling (ATM-ATR-TP53)
(Figure 4). IHC studies with anti-p21 and anti-p27 antibodies
confirmed the damage response activation in all sporadic CAS
individuals (Table 1 and Figure 2). Therefore, our results
suggest a relation between telomere instability (familial CAS)
and altered damage signaling (sporadic CAS) on 1 hand, and
increased cell cycle arrest leading to the cessation of cell
division on the other. Our observation is in agreement with
previous studies in which overexpression of TP53 was








































Figure 3. VEGF (vascular endothelial growth factor)-angiogenesis signaling and cell cycle regulation pathways. VEGF signaling is a growth
factor pathway to stimulate vasculogenesis and angiogenesis. A, MAPK/ERK signaling regulates cell proliferation. B, AKT/PI3K signaling is
related to protein synthesis and cell cycle signaling. Locations of anti–P-ERK and anti–P-S6 used in IHC studies are also shown in the pathway
(white arrows). C, Damage-signaling pathway. AKT/PI3K signaling inhibits apoptosis, senescence, and cell cycle arrest through inhibition of
FOXO, which in turn positively regulates p21 and p27 activity.
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patients.19 Somatic activating mutations in the VEGF-
angiogenesis pathway were also found in tumor tissue of all
sporadic CAS individuals (Figures 2 and 4). Similar studies
performed in angiosarcomas also uncovered somatic driver
mutations in the VEGF/PLCG1 angiogenesis pathway.18,20,21
Constitutional Cell Cycle Arrest May Fuel the
Acquisition of Somatic Mutations in the
Angiogenesis Pathway in Angiosarcomas
Activation of damage signaling in both familial (POT1 muta-
tions carriers) and sporadic angiosarcomas (ATM-ATR-TP53
mutation carriers) induced constitutional senescence and
reduced cell division (Figure 2). Our results strongly suggest a
correlation between constitutional cell cycle arrest and the
acquired somatic mutations in the VEGF-angiogenesis path-
way that drive angiosarcoma formation. Moreover, increased
cell cycle arrest due to POT1 malfunction also uncovered
somatic angiogenesis activation in tumors other than cardiac
angiosarcomas. Damage response signaling and the VEGF-
signaling pathway are mutually regulated (Figure 3). Recently,
telomere biology and the PI3K pathway (angiogenesis) were
also shown to be functionally connected, and phosphorylation
activity of the PI3K/AKT pathway was demonstrated to affect
telomere stability in vitro.35 In vitro studies with stem cells
from Pot1a knockout mice with increased telomere dysfunc-
tion also suggested a correlation with increased prolifera-
tion.36 Our results indicate that the observed cell cycle
deregulation may interfere with apoptosis. This bypass of
apoptosis would permit the acquisition of somatic mutations.
In addition, cells carrying somatic mutations in genes involved
in attenuating cell cycle arrest, which depletes progenitor
stem cells in nontumor tissues, may undergo positive
selection. A bypass of apoptosis was also suggested in
studies in which POT1 was inactivated in vitro, and induced
genomic instability enabled cancer cells to acquire additional
mutations and conferred aggressive behavior. Attenuation of
the damage response was suggested to allow tumor cells to
bypass the proliferation defect imposed by POT1 inhibition.36
Therefore, under senescence conditions, activating somatic
mutations in the angiogenesis pathway would acquire an
important role to replenish the depleted tissue. However, the
mutations found in the angiogenesis pathway would con-
tribute to angiosarcoma formation and progression.
Clinical Significance of the Identified Mechanism
Activation of the VEGF-angiogenesis pathway was found in all
studied individuals with AS (familial and sporadic). However,
our IHC studies revealed 2 different staining patterns that
correlated with the location of the somatic mutations
(Figure 2). Tumors with mutations in the AKT-PI3K signaling
pathway (F1, F2, F3, and T1) were only positively stained with
the anti-P-S6 antibody (Table 1 and Figure 4). The individuals
with mutations only in the MAPK/ERK signaling pathway
(NT1, NT2 and the papillary thyroid tumor of F2) or in both
molecular signaling pathways (T3 and T4) were positively
stained with both antibodies (Table 1). Therefore, different
somatic alterations regarding increased angiogenesis may
occur in response to senescence. These results give impor-
tant clues regarding the diagnosis and classification of
angiosarcomas.
Our results also have an important clinical relevance
regarding treatment and translational research. Inhibition of
angiogenesis may be useful to stop tumor progression.37
However, angiogenesis inhibition would mitigate the effect of
the driving somatic mutations but would not revert cell cycle
arrest or the suggested bypass of apoptosis and would
therefore not curtail the acquisition of new somatic mutations.
Treatment with PI3K inhibitors of patient-derived xenografts
also showed increased telomeric DNA damage.35 Our results
suggest that further studies regarding ATM/ATR, damage
signaling and cell cycle inhibition activity might lead to
recovering cell cycle control and preventing the acquisition of
somatic mutations, including in asymptomatic patients carry-
ing POT1 mutations. Regarding this issue, the second
Figure 4. Genes with mutations in the studied CAS individuals. Genes are distributed
considering the gene ontology among telomere instability and damage response or
VEGF (vascular endothelial growth factor)-angiogenesis signaling pathways. Exomes
from normal/tumor tissues of 3 patients (F1, F2, and F3) carrying the constitutional
POT1 p.Arg117Cys mutation (orange) and 3 sporadic CAS individuals not carrying
mutations in the POT1 gene (NT1, NT2, and NT3) were sequenced. Constitutional
mutations refer to variants found in blood samples and found in common in both N and
T tissues (red). Mutations found only in tumor tissue were considered somatic (purple).
Only tumor tissue from another 4 sporadic CAS individuals (T1 to T4) was also
sequenced. A distinction between first event and somatic variants could not be made
for the mutations found in these individuals (blue). Less stringent frequency filtering
corresponds to a minor allele frequency <0.05 (light purple) instead of <0.01 (light
blue). AS indicates angiosarcoma; CAS, cardiac angiosarcoma; N, normal tissue; P.
thyroid, papillary thyroid tumor; T, tumor tissue.
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sequencing experiment with the IBM Watson platform also
pointed to the damage-signaling pathway as a therapeutic
target. Actionable variants in the TP53 gene were highlighted
in both studied CAS individuals (T1 and T4). Therefore,
although somatic driver variants were found to occur in the
angiogenesis pathway, only damage response signaling was
found actionable for both studied angiosarcomas (Tables S4
and S5).
In summary, our current results demonstrate that inhibi-
tion of POT1 gene function and damage response malfunc-
tion both activate ATR-dependent DNA damage signaling,
which increases cell cycle arrest that would diminish cell
proliferation in constitutional tissue, and that triggers
somatic activating mutations in the angiogenesis pathway
in angiosarcomas. Interestingly, our results and the 2
previously studied CAS patients16,17 suggest a strong
correlation between constitutional mutations in the POT1
gene, somatic activating mutations in the KDR gene, and
CAS development. Importantly, the same mechanism was
observed in tumor types different from cardiac tumors for
patients carrying POT1 mutations and long telomeres
(Figure 2). The significance of this mechanism needs to be
further evaluated, and it is conceivable that POT1 mutations
lead to the same acquired somatic alterations in other
tissues and tumor types such as glioma, melanoma, or
colorectal cancer.7 Therefore, mutations found in the POT1
gene and other genes involved in DNA damage-response
signaling (ATR/ATM and TP53) in the studied cardiac
angiosarcomas correlate with constitutional cell cycle arrest,
which would deplete the progenitor cells and trigger tissue
stress. This tissue stress would give rise to a bypass of the
apoptotic regulation, which permits the acquisition of
multiple somatic events. In all studied CAS cases (patients
with familial CAS carrying the POT1 mutation and patients
with sporadic CAS), somatic activating mutations were found
in the angiogenesis pathway, which drives tumor formation.
At a translational level, inhibition of angiogenesis might be
useful to halt tumor progression. However, inhibition of
angiogenesis would not reverse cell cycle arrest or the
suggested bypass of apoptosis in constitutional asymp-
tomatic tissue. Instead, the use of ATM/ATR activity
inhibitors might restore cell cycle control and prevent the
acquisition of somatic mutations.
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Table S1. Filtered somatic variants found in the WES of POT1 p.Arg117Cys carriers, one CAS and one breast AS with papillary thyroid cancer. 
Genes previously shown to be involved in the corresponding pathology are highlighted in grey. 
Pathology Chr Gene Position REF ALT ALT allele fraction 
Amino acid 
change dbSNP Cosmic GMAF ExAC 
CAS 1 TMEM52 1850627 CAGCGGCAGG C 0.224 L26del COSM1167507 - - 
1 RCC1 28858834 G A 0.184 G169Asp - - - 
1 CELSR2 109792751 T C 0.432 L17P rs200277265 COSM1200708 - - 
1 NOTCH2 120612234 G C 0.234 - - - - 
1 NOTCH2NL 145248838 A G 0.232 - rs201204854 - - 
1 ARNT 150849103 C A 0.165 - rs10305649 0.0289 0.05 
1 LOR 153233990 T G 0.212 Y189D - - - 
2 NRXN1 50765449 C T 0.346 W735* - - - 
2 ANKRD36 97820478 G A 0.432 c.1260+3D rs79756591 COSM1632174,COSM1632175 - - 
2 RABL2A 114386168 C T 0.218 - - - - 
2 HS6ST1 129075877 G T 0.214 D87E - - - 
2 HS6ST1 129075939 T A 0.168 K67* rs202247387 COSM1129578 - - 
2 HOXD11 176972061 G C 0.344 - - - - 






Q30_Q38del rs72362780 COSM1406147 - - 
2 NGEF 233748132 C T 0.234 R549H - - - 
3 FANCD2 10088266 G T 0.434 c.1137G>T+3D rs72492997 - - 
4 KDR 55968550 CATT C 0.424 N704del - - - 
4 ALB 74280882 G A 0.546 V397M - - - 
4 DSPP 88537069 T TGATAGCAGC 
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 4 CENPE 104119549 G C 0.212 - - 
 - - 
 4 SYNPO2 119951749 C T 0.188 R607* - 
 - - 
 4 CBR4 169931326 CA C 0.434 - rs67305871 
 - - 
 6 ATAT1 30595639 G C 0.465 G79A - 
 - - 
 6 HLA-DRB5 32497905 G A 0.365 R33* rs71549219 
 - - 
 6 HBS1L 135290447 T G 0.345 E609D - 
 - - 
 












 7 TRBV5-5 142148969 A T 0.498 L101* - 
 - - 
 10 ARMC4 28250610 C A 0.370 D425Y - 
 - - 
 10 FGFR2 123325217 C T 0.430 c.111-1 - 
 - - 
 
11 MUC6 1030228 A C 0.708 C334G rs200980330 
COSM1603961, 
COSM1603962 - - 
 11 CLCF1 67141148 AT A 0.278 - - 
 - - 
 11 PDE2A 72301235 CGT C 0.234 Y252SfsTer74 - 
 - - 
 12 DDX11 31237978 C T 0.188 R186W rs74087925 
 - - 
 12 PRKAG1 49397570 C A 0.234 V234F - 
 - - 
 
12 KMT2D 49434325 G A 0.436 R2410* 
 
COSM144609, 
COSM1299436 - - 
 12 KMT2D 49444088 GGA G 0.298 L1094PfsTer20 - 
 - - 
 14 ZFP36L1 69256806 T G 0.436 K154T - 
 - - 
 16 TOX3 52484238 G A 0.186 Q31L - 
 - - 
 16 PSMB10 67970188 G C 0.688 R58G  COSM139019 - - 
 17 SHPK 3524660 CGGCGAT C 0.444 Il30_Al31del - - - 
 19 RHPN2 33490566 T C 0.212 Q384R - 
 - - 
 19 RHPN2 33490585 G A 0.388 Q378* rs78615454 COSM1318333 - - 
 
22 POTEH 16287784 C T 0.268 W34* rs200375190 
 0.006 - 
 22 SRRD 26879946 GGAGGCGGC G 0.160 Al33_A39del rs66831137 









X SLC25A5 118604444 G C 0.426 R236P rs114413582 
 - - 




7 COSM746 -  
 4 TRIM2 154217059 G A 0.656 V461M   - <0.0001 
 5 EIF4E1B 176070736 G A 0.655       - <0.0001 
 10 HPSE2 100503738 C T 0.258 R229H     - 0.00473 
 11 TENM4 78516508 G A 
0.288 
R670W   
- <0.0001 
 11 CBL 119148966 T G 0.212 C396G  COSM34074 -  
 12 VWF 6103147 T C 0.214 Y2160C   - <0.0001 
 13 PARP4 25021323 A G 0.344 I1039T rs73172125 COSM147647 - 0.347 
 13 COL4A2 111160303 C T 0.256 A1539V   - <0.0001 
 15 CSPG4 75982085 C T 0.156 E441K rs79463888 COSM1317754 - 0.15 
 20 BPIFB4 31680303 C A 0.128 P395T   -  
 20 PLCG1 39795452 C G 0.434 L752V   -  




2 COSM1027261 - <0.0001 
Papillary 3 RASSF1 50369082 C T 0.212 R227H   - <0.0001 
Thyroid 6 MDGA1 37606032 C T 0.234 V909I  COSM1600157 - <0.0001 
 6 ARID1B 157528658 G A 0.168 R2168Q   - <0.0001 




2 COSM476 - <0.0001 
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Table S2. Filtered variants found in the WES of F3 patient affected with CAS (POT1 p.R117C carrier).   
         
Chr Gene Symbol 
Genomic 
Position REF ALT Fraction HGVSp Existing Variation  GMAF 
chr1 KYAT3 88949093 A T 0.128 ENSP00000260508.4:p.Leu380Gln rs144984854 0.0006 
chr2 ANKRD36 97211741 G A 0.436 ENSP00000391950.2:p.Val1157Met rs10194525  
chr6 HLA-DRB1 32580249 G C 0.310 ENSP00000353099.5:p.Thr262Arg   
chr10 EEF1AKM 124774782 C T 0.168 ENSP00000357829.2:p.Ala98Thr rs199727427 0.0006 
chr13 PARP4 24447185 A G 0.304 ENSP00000371419.3:p.Ile1039Thr   
chr17 MYH13 10306461 G A 0.344 ENSP00000404570.3:p.Arg1822Trp rs116935297 0.007 
chr17 MAP2K3 21300875 G T 0.456 ENSP00000345083.4:p.Arg94Leu rs56067280  
chr18 ANKRD30B 14843024 C G 0.478 ENSP00000351875.4:p.Pro918Ala rs180690700 
chr19 COLGALT1 17560463 C G 0.268 ENSP00000252599.3:p.Leu163Val rs764429704 
chr17  63491216 C T 0.675 ENSP00000464149.1:p.Thr342Met rs3730043 0.0034 
chr1 VPS13D 12249234 A C 0.677 ENSP00000478104.1:p.Gln153His rs116415833 0.0018 
chr1 FAM131C 16058547 G A 0.104 ENSP00000364814.4:p.Arg245Trp rs77667563  
chr1 CROCC 16940041 G C 0.126 ENSP00000364691.4:p.Asp586His rs9435714  
chr1 KDF1 26952098 A G 0.456 ENSP00000319179.5:p.Cys95Arg rs148853297 
chr1 PPCS 42456962 A T 0.546 ENSP00000361642.3:p.Arg133Trp rs199807362 
chr1 IPP 45716925 G A 0.344 ENSP00000379739.3:p.Arg427Cys rs142095376 0.0002 
chr1 PODN 53078994 G A 0.778 ENSP00000308315.5:p.Arg543His rs61999355 0.003 
chr1 FAM151A 54619889 C G 0.128 ENSP00000306888.2:p.Lys79Asn rs114883650 0.0144 
chr1 RBMXL1 88983615 C G 0.376 ENSP00000446099.1:p.Gly71Ala rs111779380 
chr1 TSPAN2 115072962 C G 0.201 ENSP00000358529.2:p.Gly39Arg rs147800870 0.0004 
chr1 PDE4DIP 149005208 C T 0.567 ENSP00000358363.4:p.Arg1396Trp rs2798901  
chr1 FLG2 152351277 G A 0.234 ENSP00000373370.4:p.Ser2170Phe rs201200591,COSM896166 
chr1 CRNN 152409620 A G 0.198 ENSP00000271835.3:p.Ser488Pro   
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chr1 KIF14 200592110 T G 0.567 ENSP00000356319.4:p.Lys928Thr rs150766596 
chr1 PKP1 201322032 G A 0.436 ENSP00000263946.3:p.Glu489Lys rs748085816 




chr1 RHOU 228743354 G A 0.676 ENSP00000355652.3:p.Val131Met   
chr1 EDARADD 236482309 C T 0.398 ENSP00000335076.4:p.Ser103Phe rs114632254,CM114961 0.013 
chr1 OR2T3 248473745 G A 0.298 ENSP00000352604.2:p.Cys132Tyr rs148025314 
chr1 OR2T34 248573866 G A 0.126 ENSP00000330904.2:p.Arg298Cys rs148590921 
chr1 OR2T27 248650526 T C 1.000 ENSP00000342008.3:p.Tyr120Cys   
chr2 MBOAT2 8873294 C T 0.107 ENSP00000302177.3:p.Val233Ile rs34573615 0.0142 
chr2  47087059 C A 0.172 ENSP00000408527.2:p.Met232Ile rs184422124 0.0008 
chr2 ASB3 53765485 G C 0.243 ENSP00000263634.2:p.Leu30Val rs36020289 0.0056 
chr2 TSPYL6 54255416 G A 0.778 ENSP00000417919.2:p.Arg246Cys rs17189743 0.0204 
chr2 USP34 61278194 G A 0.166 ENSP00000381577.2:p.Pro1802Ser   
chr2 ANKRD36C 95944662 T A 0.214 ENSP00000403302.1:p.Asn486Tyr rs77220524  
chr2 ASTL 96132701 C T 0.463 ENSP00000343674.2:p.Arg159His rs61735195 0.0066 
chr2 NIFK 121732168 C T 0.184 ENSP00000285814.4:p.Glu94Lys rs751855520 
chr2 LCT 135817693 T A 0.564 ENSP00000264162.2:p.Lys452Met   
chr2 LRP1B 140868259 G A 0.804 ENSP00000374135.3:p.Leu1392Phe rs200955532,COSM1007053 
chr2 NMI 151275501 G A 0.756 ENSP00000243346.5:p.Thr206Met rs199573903 0.0002 
chr2 SLC39A10 195716880 A G 0.278 ENSP00000386766.3:p.His647Arg rs755523552 
chr2 TNS1 217882350 A C 0.674 ENSP00000171887.4:p.Ile311Met rs11680854 0.0104 
chr2 ESPNL 238131340 A G 0.201 ENSP00000339115.3:p.Lys876Glu rs149541007 0.0062 
chr3 FANCD2 10065867 G C 0.436 ENSP00000287647.3:p.Cys758Ser rs540805431 0.0002 
chr3 TTC21A 39138609 G A 0.678 ENSP00000398211.2:p.Glu1291Lys rs80238762 0.0058 
chr3 DNAH1 52360039 G A 0.322 ENSP00000401514.2:p.Val1511Met rs61734638 0.0084 
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chr3 ZNF717 75737101 G T 0.201 ENSP00000419377.1:p.Pro791His rs79138891  
chr3 ZNF717 75737127 A C 0.128 ENSP00000419377.1:p.His782Gln rs79811623  
chr3 ZNF717 75737622 T A 0.344 ENSP00000419377.1:p.Arg617Ser rs76175438  
chr3 ZNF717 75737840 C T 0.166 ENSP00000419377.1:p.Glu545Lys rs76496075  
chr3 ZNF717 75738575 G A 0.236 ENSP00000419377.1:p.Arg300Cys rs1962893  
chr3 OR5K1 98469710 T C 0.768 ENSP00000373193.2:p.Leu45Ser rs200654905 0.003 
chr3 BBX 107716685 C T 0.924 ENSP00000319974.8:p.Arg81Trp rs142400819 0.003 
chr3 ARHGEF26 154225981 C G 0.440 ENSP00000348828.4:p.Asn687Lys   
chr3 GPR149 154428985 G C 0.778 ENSP00000374390.2:p.Pro211Ala rs774089990 
chr3 MUC20 195726080 G C 0.234 ENSP00000414350.2:p.Asp493His   
chr3 MUC20 195729690 C G 0.128 ENSP00000414350.2:p.Ser671Cys   
chr3 MUC4 195762138 C A 1.000 ENSP00000417498.3:p.Ala4821Ser CM066583  
chr3 MUC4 195789859 G A 0.184 ENSP00000417498.3:p.Thr574Ile   
chr4 IDUA 987896 C G 0.134 ENSP00000247933.4:p.His82Gln rs148775298 0.0012 
chr4 HTT 3207344 G A 0.310 ENSP00000347184.5:p.Gly2047Arg rs181217572 0.0004 
chr4 TLR1 38796634 G A 0.780 ENSP00000354932.2:p.Pro733Leu rs5743621 0.0126 
chr4 KDR 55098758 G C 0.654 ENSP00000263923.4:p.Thr771Arg COSM94566,COSM4381082 
chr4 UGT2B15 68670105 T G 0.388 ENSP00000341045.5:p.Ser172Arg rs200638397 0.0002 
chr4 RUFY3 70806627 C G 0.124 ENSP00000370394.3:p.Leu611Val rs754675264 
chr4 CCSER1 90308466 G C 0.432 ENSP00000425040.1:p.Ser61Thr rs184253075 0.0008 
chr4 PDLIM5 94455353 A G 0.567 ENSP00000480359.1:p.Lys22Arg rs75841704 0.0078 
chr4 UNC5C 95170263 C T 0.128 ENSP00000406022.1:p.Ala841Thr rs34585936 0.0184 
chr4 QRFPR 121380442 A C 0.214 ENSP00000377948.2:p.Val69Gly rs34270076 0.0076 
chr4 CBR4 169002197 C A 0.678 ENSP00000303525.3:p.Val137Phe   
chr4 CBR4 169002200 T A 0.455 ENSP00000303525.3:p.Ile136Phe   
chr4 TLR3 186084674 C A 0.134 ENSP00000296795.2:p.Ala839Asp rs201540925,COSM4584973 0.0002 
chr5 SLC9A3 488354 C T 0.436 ENSP00000264938.3:p.Val213Ile rs143027124 
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chr5 ADGRV1 90705420 G A 0.124 ENSP00000384582.2:p.Ala2803Thr rs111033530 0.0048 
chr5 MARCH3 126878360 C T 0.356 ENSP00000309141.5:p.Arg143Gln rs138413676 
chr5 LECT2 135951324 C T 0.304 ENSP00000274507.1:p.Gly63Glu rs149560293 0.0068 
chr5 PCDHGA6 141374360 G A 0.256 ENSP00000429601.1:p.Glu93Lys rs200765071 
chr5 PCDH12 141945665 C T 0.732 ENSP00000231484.3:p.Gly1091Ser rs779814208 
chr5 SCGB3A2 147881560 G A 0.652 ENSP00000296694.4:p.Gly57Asp rs140599638 0.0004 
chr5 SLC36A2 151343594 C A 0.224 ENSP00000334223.4:p.Gly87Val rs77010315,CM086960 0.005 
chr5 GFPT2 180301596 T C 0.364 ENSP00000253778.8:p.Arg673Gly   
chr6 SOX4 21594616 C G 0.578 ENSP00000244745.1:p.Leu28Val rs140231408,COSM3697699 0.0066 
chr6 BTN2A2 26392401 G A 0.576 ENSP00000349143.4:p.Ala336Thr rs142803339,COSM3745097 0.0092 
chr6 HLA-A 29944253 G C 0.168 ENSP00000379873.1:p.Asp251His 
CD994645,COSM5446135,COSM5446134,COSM459
3407 
chr6 PPP1R10 30609877 C G 0.222 ENSP00000365694.2:p.Gly23Ala   
chr6 HLA-DRB1 32580779 C T 0.128 ENSP00000353099.5:p.Ala244Thr rs3830125  
chr6 HLA-DRB1 32589669 G C 0.201 ENSP00000353099.5:p.Pro25Arg rs148093782 
chr6 HLA-DQB2 32757848 T C 0.344 ENSP00000396330.2:p.Ser228Gly rs9276572  
chr6 PPIL1 36871822 C G 0.134 ENSP00000362803.5:p.Cys36Ser rs12194408 0.0098 
chr6 PTK7 43130655 G A 0.276 ENSP00000418754.1:p.Arg277His rs78949718 0.0028 
chr6 POLR1C 43520104 C T 0.128 ENSP00000361465.3:p.Arg141Cys rs148385032 0.0014 
chr6 DST 56552557 C T 0.128 ENSP00000307959.7:p.Gly3155Glu rs775546048 
chr6 TTK 80035318 C T 0.166 ENSP00000358813.2:p.Leu609Phe rs540538876 0.0002 
chr6 PNRC1 89081009 C T 0.124 ENSP00000336931.3:p.Pro39Ser rs2231267 0.0056 
chr6 ARMC2 108953073 C T 0.278 ENSP00000376417.4:p.Thr546Met rs61741720 0.0132 
chr6 VNN1 132683243 T C 0.128 ENSP00000356905.4:p.Tyr480Cys rs567530094 0.0002 
chr6 SHPRH 145922832 G A 0.243 ENSP00000356475.2:p.Arg1184Cys rs148401398 0.0014 
chr7 AMZ1 2709683 G T 0.376 ENSP00000308149.4:p.Cys272Phe rs148137749 0.0006 
chr7 SDK1 3962743 G A 0.455 ENSP00000385899.2:p.Gly441Arg rs139796765 0.0058 
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chr7 PSPH 56021118 T C 0.295 ENSP00000378854.3:p.Asp32Gly   
chr7 GATAD1 92456449 C T 0.184 ENSP00000287957.3:p.Arg233Trp rs34768413 0.007 
chr7 FBXO24 100590263 A C 0.128 ENSP00000416558.2:p.Glu114Asp rs545357401 0.0002 
chr7 POT1 124863547 G A 0.457 ENSP00000350249.3:p.Arg117Cys rs780936436 
chr7 CPA2 130289628 C A 0.335 ENSP00000222481.4:p.Leu381Met rs146796996 0.0012 
chr7 TRBV20-1 142627134 A T 0.310 ENSP00000374917.3:p.Arg24Trp   
chr7 PRSS1 142750558 C G 0.436 ENSP00000308720.7:p.Ala15Gly rs200665515,COSM3723223 
chr7 PRSS1 142750660 G T 0.567 ENSP00000308720.7:p.Gly49Val rs138464021 
chr7 PRSS1 142750672 T A 0.668 ENSP00000308720.7:p.Ile53Asn rs149246646 
chr7 PRSS1 142752506 G T 0.574 ENSP00000308720.7:p.Gly177Val   
chr7 SSPO 149802064 C T 0.256 ENSP00000485256.1:p.Ser2508Phe rs140977594 0.0056 
chr7 KMT2C 152247922 C T 0.446 ENSP00000262189.6:p.Gly838Ser COSM4591270 
chr7 KMT2C 152265180 C T 0.675 ENSP00000262189.6:p.Asp348Asn rs201834857,COSM228110 
chr7 VIPR2 159031954 C T 0.788 ENSP00000262178.2:p.Cys362Tyr rs147214125 0.0004 
chr8 SGCZ 14108196 G A 0.476 ENSP00000371512.1:p.Pro196Leu rs145213189 0.0004 
chr8 PDGFRL 17642653 T A 0.324 ENSP00000444211.1:p.Ile327Asn rs35346456 0.0022 
chr8 MTUS1 17653257 C G 0.222 ENSP00000262102.6:p.Glu1105Gln rs61733705 0.0066 
chr8 MTUS1 17684434 T G 0.166 ENSP00000262102.6:p.Lys911Thr rs61748836 0.0046 
chr8 CYP7A1 58497114 A G 0.436 ENSP00000301645.3:p.Leu133Pro   
chr8 CSPP1 67116017 C G 0.657 ENSP00000262210.5:p.Ser459Cys rs146431326 0.0012 
chr8 NBN 89971232 G A 0.436 ENSP00000265433.3:p.Arg215Trp rs34767364,CM044022 0.001 
chr8 PABPC1 100709584 G A 0.566 ENSP00000313007.5:p.Arg374Cys rs200409148 
chr8 PABPC1 100709589 T C 0.534 ENSP00000313007.5:p.Glu372Gly rs201076736 
chr8 PABPC1 100709611 C A 0.128 ENSP00000313007.5:p.Val365Leu rs202074479 
chr8 PABPC1 100717815 G C 0.312 ENSP00000313007.5:p.Ala154Gly rs113614781 
chr8 DEPTOR 119965343 G C 0.122 ENSP00000286234.5:p.Glu179Asp rs766410544 
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chr9 ADAMTSL 18684733 G T 0.184 ENSP00000369921.4:p.Ala503Ser 
rs149221350,COSM3906436,COSM39
06437 0.0012 
chr9 LINGO2 27949346 A C 0.345 ENSP00000369328.1:p.Ile442Met   
chr9 SHC3 89042122 G A 0.304 ENSP00000364995.4:p.Pro422Ser rs771704230,COSM24411 
chr9 OR13C5 104599179 G A 0.431 ENSP00000363911.2:p.Pro79Ser rs7025570,COSM4163183 
chr9 TRIM32 116698344 G A 0.128 ENSP00000408292.1:p.Arg201His   
chr9 LAMC3 131072789 C T 0.655 ENSP00000354360.4:p.Ser1124Phe rs113259170 0.0032 
chr9 GBGT1 133153893 C T 0.756 ENSP00000361110.3:p.Arg243His rs143563851,COSM4163479 0.001 
chr10 CUBN 16890385 G A 0.678 ENSP00000367064.4:p.Ala2914Val rs45551835,COSM32707 0.0064 
chr10 NPY4R 46462341 C A 0.234 ENSP00000363431.1:p.Ala99Ser   
chr10 GPRIN2 46549695 C A 0.112 ENSP00000363436.1:p.Val348Leu rs4926046  
chr10 GPRIN2 46550133 C A 0.324 ENSP00000363436.1:p.Gly202Trp rs11204658  
chr10 GPRIN2 46550598 C T 0.436 ENSP00000363436.1:p.Val47Met   
chr10 GPRIN2 46550622 G C 0.234 ENSP00000363436.1:p.Leu39Val   
chr10 LHPP 124517198 G A 0.536 ENSP00000357835.5:p.Asp215Asn rs140823928 0.0038 
chr10 CTBP2 124994530 G A 0.598 ENSP00000311825.6:p.Ser780Phe rs374871777,COSM2021369,COSM2021368 
chr10 CTBP2 124994542 C T 0.504 ENSP00000311825.6:p.Ser776Asn rs78155918  
chr10 CTBP2 124994563 A T 0.544 ENSP00000311825.6:p.Leu769Gln rs150320719 
chr10 CTBP2 124994577 C A 0.657 ENSP00000311825.6:p.Gln764His rs80025996,COSM5764564,COSM5764563 
chr10 CTBP2 125002983 T G 0.346 ENSP00000311825.6:p.Asp652Ala rs796433756 
chr10 CTBP2 125003006 T C 0.310 ENSP00000311825.6:p.Ile644Met rs112239066 
chr10 CTBP2 125003010 C T 0.215 ENSP00000311825.6:p.Arg643Gln rs760489730,COSM5620576,COSM5620575 
chr10 CTBP2 125003036 C A 0.166 ENSP00000311825.6:p.Lys634Asn rs201760950,COSM4441587,COSM4441586 
chr10 CTBP2 125003065 T A 0.184 ENSP00000311825.6:p.Ile625Phe rs75794788,COSM4144456,COSM4144455 
chr10 CTBP2 125003091 G A 0.345 ENSP00000311825.6:p.Ala616Val rs3198935  
chr10 CTBP2 125003357 G A 0.128 ENSP00000311825.6:p.Thr605Met rs768573864,COSM2021395,COSM2021394 
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chr10 CTBP2 125003410 C G 0.215 ENSP00000311825.6:p.Glu587Asp rs74705267,COSM4144460,COSM4144459 
chr10 CTBP2 125003448 G C 0.166 ENSP00000311825.6:p.Leu575Val rs3198920  
chr10 CTBP2 125003450 G A 0.376 ENSP00000311825.6:p.Pro574Leu rs796256730,COSM5620578,COSM5620577 
chr10 CTBP2 125003460 G T 0.435 ENSP00000311825.6:p.His571Asn rs796388243 
chr10 CTBP2 125003466 G T 0.243 ENSP00000311825.6:p.Pro569Thr   
chr10 CTBP2 125003468 C A 0.213 ENSP00000311825.6:p.Gly568Val rs368195398 
chr10 CTBP2 125003470 G T 0.178 ENSP00000311825.6:p.Asn567Lys rs797010536 
chr11 MUC6 1016961 G A 0.166 ENSP00000406861.2:p.Thr1947Ile rs773824783 
chr11 MUC6 1017069 G A 0.801 ENSP00000406861.2:p.Thr1911Met rs80333708  
chr11 MUC6 1017135 G A 0.726 ENSP00000406861.2:p.Thr1889Ile rs747429892 
chr11 MUC6 1017183 G T 0.405 ENSP00000406861.2:p.Pro1873Gln rs34844844 0.0004 
chr11 MUC6 1017337 T C 0.435 ENSP00000406861.2:p.Thr1822Ala rs76686156  
chr11 MUC6 1018042 A G 0.235 ENSP00000406861.2:p.Ser1587Pro rs200364398 
chr11 MUC6 1018473 A T 0.387 ENSP00000406861.2:p.Leu1443His rs112923701 
chr11 OR51J1 5403408 C T 0.468 ENSP00000332473.1:p.Ser271Phe rs183738872 0.0008 
chr11 SAA2-SAA4 18245916 A G 0.234 ENSP00000485552.1:p.Val75Ala rs71469388  
chr11 LRP4 46895950 G A 0.435 ENSP00000367888.1:p.Arg373Trp rs118009068 0.0106 
chr11 FOLH1 49186715 G A 0.665 ENSP00000256999.2:p.Arg190Trp rs75111588  
chr11 OR4C46 54603244 C T 0.657 ENSP00000329056.1:p.Cys252Tyr rs11246608  
chr11 OR4C46 54603280 G A 0.879 ENSP00000329056.1:p.Ser240Phe rs11246607  
chr11 OR9G1 56700722 A G 0.342 ENSP00000309012.1:p.Tyr112Cys rs4990194 0.0056 
chr11 OR9G1 56700892 C T 0.210 ENSP00000309012.1:p.Arg169Cys rs11228733 0.0008 
chr11 OR9G1 56701223 T A 0.128 ENSP00000309012.1:p.Val279Glu rs79251113  
chr11 ESRRA 64315848 T C 0.184 ENSP00000384851.1:p.Leu385Pro rs201072913 
chr11 ESRRA 64315856 C T 0.376 ENSP00000384851.1:p.Leu388Phe rs79204587  
chr11 ESRRA 64315859 C T 0.435 ENSP00000384851.1:p.Arg389Cys rs80310817  
chr11 ACTN3 66554587 C T 0.231 ENSP00000422007.1:p.Pro217Leu rs370740496 
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chr11 USP35 78210302 G A 0.768 ENSP00000431876.1:p.Arg816His rs75370284 0.0128 
chr11 TRIM49C 90041372 C A 0.465 ENSP00000388299.1:p.Thr394Asn rs75119043,COSM3998623,COSM3998622 
chr11 MAML2 96093510 C T 0.376 ENSP00000434552.1:p.Gly174Asp rs61749254 0.0042 
chr11 SORL1 121496918 G A 0.346 ENSP00000260197.6:p.Glu270Lys rs117260922 0.0078 
chr11 OR8B2 124382854 G A 0.567 ENSP00000364152.2:p.Leu164Phe rs886202  
chr12 WNK1 827047 T A 0.234 ENSP00000341292.5:p.Leu313Gln   
chr12 FOXM1 2858912 G A 0.128 ENSP00000342307.2:p.Pro711Leu rs28919870 0.0044 
chr12 CRACR2A 3696811 A C 0.345 ENSP00000409382.2:p.Asp63Glu rs144314920 0.0004 
chr12 KLRC2 10435931 C G 0.376 ENSP00000371327.2:p.Arg19Pro rs75545535  
chr12  10435931 C G 0.346 ENSP00000437563.1:p.Arg19Pro rs75545535  
chr12 TAS2R19 11021703 A G 0.205 ENSP00000375091.2:p.Phe290Ser   
chr12 TAS2R19 11021868 A C 0.346 ENSP00000375091.2:p.Leu235Arg rs763119571 
chr12 TAS2R31 11030522 G A 0.145 ENSP00000375093.2:p.Pro272Ser rs763119976 
chr12 TAS2R31 11031043 A G 0.754 ENSP00000375093.2:p.Leu98Pro rs73049067  
chr12 TAS2R31 11031194 G C 0.304 ENSP00000375093.2:p.Leu48Val rs760444623 
chr12 TAS2R30 11134103 G C 0.166 ENSP00000444736.1:p.Leu48Val rs113026132 
chr12 PTPRO 15503912 C G 0.456 ENSP00000281171.4:p.Asn370Lys rs61754411 0.009 
chr12 CCDC65 48918345 A G 0.345 ENSP00000312706.4:p.Gln227Arg rs149640178 0.0004 
chr12 TROAP 49331358 G A 0.545 ENSP00000257909.3:p.Arg748Gln rs200487146,COSM4921428 0.0006 
chr12 RDH5 55724028 G T 0.787 ENSP00000257895.5:p.Gly238Trp 
rs62638191,CM991095,RISN_RDH5:c
.712G>T 0.0004 
chr12 MDM1 68332236 G C 0.456 ENSP00000302537.7:p.Arg4Gly rs199537908 
chr12 LRRIQ1 85153046 A C 0.476 ENSP00000376910.2:p.Asp1481Ala rs191782536 0.0018 
chr12 DNAH10 123916480 C A 0.675 ENSP00000489675.1:p.Asp3464Glu rs61745785 0.011 
chr13 MPHOSPH 19642121 G T 0.778 ENSP00000355388.4:p.Val74Phe   
chr13 PARP4 24447125 T C 0.368 ENSP00000371419.3:p.Gln1059Arg rs77269056  
chr13 PABPC3 25096638 C T 0.215 ENSP00000281589.3:p.Thr147Ile rs78432860  
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chr13 PABPC3 25096889 A G 0.786 ENSP00000281589.3:p.Lys231Glu rs78826513  
chr13 PABPC3 25096951 G T 0.745 ENSP00000281589.3:p.Met251Ile rs75281454  
chr13 PABPC3 25097154 C T 0.564 ENSP00000281589.3:p.Thr319Ile rs80261016  
chr13 PABPC3 25097291 G T 0.678 ENSP00000281589.3:p.Val365Leu rs77466429  
chr13 NEK5 52086336 G A 0.124 ENSP00000347767.4:p.Arg474Cys rs35465612 0.0042 
chr13 SLC10A2 103049340 G A 0.434 ENSP00000245312.3:p.Pro290Ser rs56398830,CM952446 0.0074 
chr14 WDR89 63599649 A T 0.376 ENSP00000378399.2:p.Asp98Glu   
chr14 WDR89 63599677 C T 0.266 ENSP00000378399.2:p.Cys89Tyr COSM5764373 
chr14 WDR89 63599684 A G 0.234 ENSP00000378399.2:p.Ser87Pro   
chr14 SYNE2 64130105 C A 0.340 ENSP00000350719.3:p.Pro4733Thr rs75568433 0.0028 
chr14 VIPAS39 77453359 C T 0.675 ENSP00000452181.1:p.Val46Met rs148360332 0.0006 
chr14 IGHV4-31 106349457 G T 0.564 ENSP00000395656.2:p.Pro61Gln rs77489245  
chr15 NUTM1 34355873 C A 0.567 ENSP00000444896.1:p.Ser622Tyr   
chr15 TYRO3 41573327 G T 0.254 ENSP00000263798.3:p.Val669Leu rs62001448  
chr15 SPATA5L1 45403247 C G 1.000 ENSP00000305494.6:p.Ser273Cys rs143453038,COSM4509821 0.01 
chr15 SPATA5L1 45403421 G T 0.654 ENSP00000305494.6:p.Gly331Val   
chr15 SNX1 64136360 G A 0.435 ENSP00000261889.5:p.Asp466Asn rs1802376 0.0074 
chr15 MYO9A 71968075 T C 0.675 ENSP00000348349.5:p.His632Arg rs552840125 0.0002 
chr16 RPL3L 1947003 C T 0.532 ENSP00000268661.7:p.Val262Met rs113956264 0.0212 
chr16 ACSM2A 20465673 G A 0.345 ENSP00000459451.1:p.Val112Met   
chr16 ACSM3 20775918 T C 0.546 ENSP00000289416.5:p.Leu100Pro rs5713 0.004 
chr16 OR16-13 33827483 G T 0.180 ENSP00000474814.1:p.Ala59Ser rs4077614  
chr16 CES1 55828971 C A 0.184 ENSP00000353720.3:p.Gly19Val rs3826190  
chr16 ZNF319 57996752 C A 0.184 ENSP00000299237.2:p.Arg505Leu rs149758697,COSM1191791 0.0002 
chr16 AARS 70252728 T A 0.215 ENSP00000261772.7:p.Lys967Met rs35744709 0.0036 
chr16 CLEC18B 74409592 C T 0.304 ENSP00000341051.5:p.Asp430Asn   
chr16 ZNF469 88437795 G C 0.128 ENSP00000402343.1:p.Arg3414Thr rs199528724,COSM1380396 0.0018 
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chr17 CTC1 8232058 G A 0.678 ENSP00000313759.8:p.Arg744Cys   
chr17 MYH13 10309647 C G 0.456 ENSP00000404570.3:p.Asp1614His rs35069886 0.0068 
chr17 MAP2K3 21300880 C T 0.765 ENSP00000345083.4:p.Arg96Trp   
chr17 MAP2K3 21304522 C T 0.678 ENSP00000345083.4:p.Thr222Met rs58609466  
chr17 KCNJ12 21415757 G A 0.234 ENSP00000463778.1:p.Glu139Lys rs76265595  
chr17 KCNJ12 21415775 G A 0.345 ENSP00000463778.1:p.Gly145Ser rs75029097 0.0002 
chr17 KCNJ12 21416124 G A 0.212 ENSP00000463778.1:p.Arg261His rs77270326  
chr17 KCNJ12 21416127 T G 0.256 ENSP00000463778.1:p.Ile262Ser rs76684759  
chr17 KCNJ12 21416474 G A 0.345 ENSP00000463778.1:p.Glu378Lys rs78547883  
chr17 SPAG5 28578086 T G 0.348 ENSP00000323300.5:p.Asn1145Thr rs138772502 0.0014 
chr17 KRTAP29-1 41302224 A T 0.678 ENSP00000375148.1:p.Cys210Ser   
chr17 KRT33B 41364890 C T 0.486 ENSP00000251646.3:p.Arg329His   
chr17 KRT33B 41369498 C T 0.567 ENSP00000251646.3:p.Glu85Lys   
chr17 ETV4 43528697 G A 0.278 ENSP00000321835.4:p.Ala426Val rs117364926 0.001 
chr17 KANSL1 46171833 T G 0.215 ENSP00000387393.3:p.Lys104Thr   
chr17 EPN3 50536971 C T 0.676 ENSP00000268933.3:p.Arg139Trp rs371737517 0.0002 
chr17 ACE 63491216 C T 0.234 ENSP00000290866.4:p.Thr916Met rs3730043 0.0034 
chr17 CSH2 63872181 T C 0.178 ENSP00000376623.2:p.Glu200Gly   
chr18 PIEZO2 10671669 C T 0.134 ENSP00000421377.3:p.Arg2706Gln rs189453524 0.0004 
chr18 OSBPL1A 24167436 A G 0.265 ENSP00000320291.3:p.Ser810Pro rs35693789 0.0094 
chr19 PODNL1 13934406 C T 0.234 ENSP00000345175.4:p.Val174Met rs781238470 
chr19 PALM3 14053817 C T 0.376 ENSP00000344996.3:p.Asp604Asn rs75841596,COSM1390897 0.0116 
chr19 WTIP 34482629 C T 0.184 ENSP00000466953.2:p.Arg219Trp   
chr19 ZNF599 34769537 C T 0.180 ENSP00000333802.6:p.Asp13Asn rs117610843 0.0058 
chr19 CYP2A6 40848628 A T 0.256 ENSP00000301141.4:p.Leu160His rs1801272,CM980517 0.0092 
chr19 PPP1R37 45144962 C T 0.324 ENSP00000221462.3:p.Leu366Phe rs146723120 0.003 
chr19 NOP53 47745650 G C 0.134 ENSP00000246802.4:p.Asp31His rs78530808 0.0158 
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chr19 LILRB2 54279040 G A 0.304 ENSP00000375629.4:p.Leu243Phe COSM1326184 
chr19 LILRA2 54574799 C A 0.356 ENSP00000251377.3:p.Leu141Ile   
chr19 LILRA2 54575019 A G 0.405 ENSP00000251377.3:p.Glu214Gly   
chr19 KIR2DL1 54773491 C A 0.546 ENSP00000336769.5:p.His77Asn   
chr19 KIR2DL1 54773534 C A 0.625 ENSP00000336769.5:p.Thr91Lys COSM5712917,COSM5545196,COSM3404605 
chr19 KIR2DL4 54804874 A G 0.645 ENSP00000339634.5:p.Tyr53Cys   
chr19 KIR3DL1 54819832 G T 0.654 ENSP00000375608.4:p.Gly159Trp   
chr19 KIR3DL2 54865893 G C 0.564 ENSP00000325525.3:p.Trp363Cys   
chr20 PYGB 25276685 T C 0.678 ENSP00000216962.3:p.Tyr234His   
chr20 ANKRD60 58218668 G A 0.564 ENSP00000396747.1:p.Pro289Ser rs41275658 0.002 
chr20 LAMA5 62317394 C T 0.304 ENSP00000252999.3:p.Ala2488Thr rs148169370 0.0048 
chr22 IGLV5-45 22376251 C T 0.234 ENSP00000374831.2:p.Leu39Phe   
chr22 GSTTP1 23998546 C A 0.215 ENSP00000492273.1:p.Arg241Met   
chr22 GSTTP1 23998547 T A 0.435 ENSP00000492273.1:p.Arg241Trp   
chr22 SUSD2 24183189 G T 0.180 ENSP00000351075.3:p.Gly70Val rs79232038  
chr22 KIAA1671 25029315 A G 0.376 ENSP00000351207.3:p.Lys439Arg   
chr22 CYP2D6 42127526 C T 0.128 ENSP00000353820.5:p.Arg365His rs1058172  
chr22 CYP2D6 42130692 G A 0.166 ENSP00000353820.5:p.Pro34Ser CM900081  
chr22 TUBGCP6 50221169 C T 0.924 ENSP00000248846.5:p.Gly1064Arg rs149231425 0.0132 
chr22 PLXNB2 50280899 A G 0.184 ENSP00000409171.1:p.Tyr1280His COSM4444878 
chrX PAGE1 49689423 T C 1.000 ENSP00000365320.3:p.Glu138Gly rs151117508 0.0079 





chrX MED12 71119383 C G 0.215 ENSP00000363193.3:p.Thr37Arg   
chrX RTL9 110450737 G C 1.000 ENSP00000419786.2:p.Gln40His rs150383653,COSM4721270 0.0003 
chrX SLC25A5 119469766 G A 0.345 ENSP00000360671.4:p.Gly73Ser rs143413528 
chrX SLC25A5 119469779 A C 0.204 ENSP00000360671.4:p.Asn77Thr rs148294496 
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Table S3. Mutations found in the WES for chromosome/telomere instability and the VEGF-angiogenesis pathway in sporadic CAS sequenced 
individuals (non-POT1 mutation carriers).  
Pathway 
 









 Amino acid 
change dbsnp MAF 



























NT2* TP53BP1 43762077 TGGGATAGG TGG 0.205  PI454-   
 ATR 142215368 GGAAGTAA - 0.215     
NT3* ATM 108200982 T A 0.166  L2450*   
 BRCA2 32912956 C A 0.166  H1488Q   
T1 BRCA1 41245120 T A 0.128  N810Y rs28897682  
 BRCA1 41246481 T C 0.257  Q356R rs1799950 0.0279 
 TP53 7578503 C T 0.451  V143M   
 TP53RK 45315786 C T 0.255  R123Q rs34983477 0.0279 
 APC2 1457002 G C 0.376  G323R rs143870588 0.0119 
T2 TP53BP2 223998162 G A 0.201  P115S   
T3 BRCA1 41245471 C T 0.312  D693N rs4986850 0.0398 







-1593   
 CDK8 26911760 C T 0.310  S62L   
 BRIP1 59861662 C A 0.567  V533L   
T4 TP53 7576876 C G 0.346  D324H   
 TP53 7578406 C T 0.134  R175H rs28934578  
 RAD51B 68331765 A T 0.126  M121L rs150928231  
 RAD51B 68352648 T G 0.104  L172W rs34094401 0.0188 
 ATM 108123551 C T 0.104  P604S rs2227922 0.0032 
 APC2 1468408 C A 0.376  A1703E rs200444154  
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Mutations  NT1** KDR 55979558 C T 0.184  V297I rs2305948 0.1310 
involved in  RASA2 141326602 T C 0.422   rs295322 0.1140 
Angiogenesis  DOCK1 128810642 C T 0.273   rs9418773 0.1230 
  RICTOR 38952300 G A 0.179  S1042L   
  IQGAP1 90996087 G A 0.189  E415K rs200988874 0.0005 
  SRC 36012590 A G 0.304  S12G   
  PIK3C2G 18691253 C T 0.435   rs12315010 0.0389 
  NRAS 115256530 G T 0.134  Q61K rs121913254  
 NT2* PDPK1 2607915 CT C 0.310  -79   
  RASA4 102246366 G A 0.124  R123W rs139960113 0.0020 
 NT3* SHOX2 157823580 TACA T 0.556  p.77_78del   
 T1 NRG2 139231255 C T 0.345  R577H rs75431091 0.0229 
  SPTAN1 131367372 A G 0.204  N1260S    
  FGF22 640065 C T 0.256  S47F   
  PIK3C2G 18443809 C A 0.107  A261E rs7133666 0.0417 
 T2 RASA2 141299289 G A 0.172  S557N   
  MAP2K1 66736993 G T 0.243     
  IQGAP1 91025227 T G 0.435  L1122R   
  VAV3 108145045 C T 0.172  E732K   
  DUSP8 1579018 T C 0.234   rs113161544 0.0640 
  PIK3C2G 18473929 C T 0.432  Q391*   
 T3 RASA2 141328901 G A 0.134  G839R   
  PLCG1 39792063 A G 0.345  S279G rs2228246 0.0952 
  RICTOR 38960053 C T 0.180  V627I   
  DUSP8 1579506 A G 0.172     
  RASA4 102235804 G A 0.102  T340I   
  RASA4 102246393 C T 0.165  E114K   
  ITGAV 187540655 G A 0.184     
 T4 PTPRQ 81004265 A C 0.436  E1589D   
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  PRKCQ 6498721 G A 0.102  A521V   
 T1; T3; T4 SPTAN1 131377915 G A 0.304  R1718H   
  T3; NT1* MAP2K1 66777404 C T 0.174  A257V   
 T4; NT2* VEGFA 43738526 C G 0.184  A28G rs201786558  
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Table S4. Actionable variants found in the sequencing experiment with IBM Watson for Genomics platform for T1 patient. 
 
Gene Actionable variant  Variant evidence (Pubmed) FDA-approved drug for 
Angiosarcoma  
Other molecules with clinical evidence (NCT)  
MSH6 p.Glu1088fs 12019211 Pembrolizunab Nivolumab (NCT0366819) 
TP53 p.Arg175His 8510927; 17401432 - Adavosertib (NCT01827384) 
    Transferrin (NCT02354547) 
ARID1A p.Pro21del 23097632 - ** 
ATR p.Ile774fs 22960745 - ** 
NOTCH p.Pro2415del 15472975*; 25564152* - ** 
 
NCT: Number of Clinical Trial 
* Similar variant within the same domain. 
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Table S5. Actionable variants found in the sequencing experiment with IBM Watson for Genomics platform for T4 patient. 
 
 
Gene Actionable variant  Variant evidence (Pubmed) FDA-approved drug for 
Angiosarcoma  
Other molecules with clinical evidence (NCT)  
CDK2A p.Arg99Pro 20340136; 19260062 - Palbociclib (NCT03239015) 
TP53 p.Val143Met 23469205 - Adavosertib (NCT01827384) 
    Transferrin (NCT02354547) 
KIT Amplification 21523721; 17189383; 16166280 Pazopanib (NCT01462630)* Pazopanib (NCT03628131) 
    Imatinib (NCT02461849) 
    Nilotinib (NC02379416) 
 
NCT: Number of Clinical Trial 
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